ContributorsPublishersAdvertisers

Dr. Abrams on the Rationale for the COSMIC-021 Trial in MSS/pMMR CRC

onclive.com
 2022-01-21

Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer. Thomas A. Abrams, MD, senior physician, Dana-Farber Cancer Institute, assistant professor of...

www.onclive.com

Comments / 0

Comments / 0